Cargando…
Novel EGFR-bispecific recombinant immunotoxin based on cucurmosin shows potent anti-tumor efficiency in vitro
Epidermal growth factor receptor (EGFR) is overexpressed in various tumors and is associated with cancer initiation, progression, and poor prognosis. Despite the achievements made by tyrosine kinase inhibitors and monoclonal antibodies in certain cases, many patients have not benefited from such tre...
Autores principales: | Zhang, Caiyun, Cai, Yumei, Dai, Xiaoxue, Wu, Jingyu, Lan, Yinxiang, Zhang, Huajin, Lu, Mengni, Liu, Junhong, Xie, Jieming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757099/ https://www.ncbi.nlm.nih.gov/pubmed/33416157 http://dx.doi.org/10.3892/or.2020.7878 |
Ejemplares similares
-
Novel cucurmosin‐based immunotoxin targeting programmed cell death 1‐ligand 1 with high potency against human tumor in vitro and in vivo
por: Zhang, Caiyun, et al.
Publicado: (2020) -
Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro
por: Deng, Cuimin, et al.
Publicado: (2017) -
Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma
por: Xie, Guiqin, et al.
Publicado: (2022) -
Bispecific human IL2‐CCR4 immunotoxin targets human cutaneous T‐cell lymphoma
por: Wang, Haoyu, et al.
Publicado: (2020) -
Clinical targeting recombinant immunotoxins for cancer therapy
por: Li, Meng, et al.
Publicado: (2017)